A Phase I trial of a live, genetically modified salmonella typhimurium (VNP20009) for the treatment of cancer by intratumoral injection
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2013
At a glance
- Drugs VNP 20009 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 02 Jan 2008 Status changed from in progress to completed.
- 11 Sep 2005 New trial record.